CNTB - Connect Bio adds 19% most since August after data presentation on lead asset

2023-03-20 13:16:55 ET

• Connect Biopharma ( NASDAQ: CNTB ) jumped ~19% most in seven months on Monday after presenting pivotal data for its lead candidate CBP-201 in moderate-to-severe atopic dermatitis (AD) at the American Academy of Dermatology Annual Meeting over the weekend.
• Announcing data from Stage 1 of the ongoing pivotal study, the company said the China-based trial met primary and secondary endpoints indicating only mild-to-moderate adverse effects.
• As for the primary goal based on Investigators Global Assessment (IGA) score for disease severity, 30.3% of CBP-201-treated patients and 7.5% of those on the placebo arm achieved an IGA score of 0-1 and a 2-point IGA reduction at week 16.
• The company is currently advancing a 36-week maintenance phase in the trial.
• Connect Biopharma ( CNTB ) shares plunged in October after announcing topline data from the study to indicate that the IL-4R? antibody reached primary and key secondary endpoints in the AD trial.

For further details see: